-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Reiterates Overweight on Capricor Therapeutics, Raises Price Target to $45

Benzinga·12/10/2025 17:25:38
Listen to the news
Piper Sandler analyst Edward Tenthoff reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Overweight and raises the price target from $20 to $45.